Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes

Conclusions: This study failed to provide any evidence to support limiting or reducing maternal dose of buprenorphine during pregnancy in order to reduce possible adverse outcomes to the infant. Findings suggest that healthcare providers can focus medication decisions on maternal opioid cravings to reduce the risk of relapse to illicit opioid use rather than out of concern for adverse infant outcomes.Eur Addict Res 2016;22:127-130
Source: European Addiction Research - Category: Addiction Source Type: research